Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model. (3rd August 2017)

• Record Type: Journal Article
• Authors: Nestvold, Janne; Wang, Meng-Yu; Camilio, Ketil A.; Zinöcker, Severin; Tjelle, Torunn Elisabeth; Lindberg, Alf; Haug, Bengt Erik; Kvalheim, Gunnar; Sveinbjørnsson, Baldur; Rekdal, Øystein
• Is Part Of: Oncoimmunology. Volume 6:Number 8(2017)
• Publication Date: 2017-08-03
• Subjects: Sarcoma -- DAMP -- Immunotherapy -- oncolytic peptide -- LTX-315; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2017.1338236
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: LTX 315 is an oncolytic peptide with potent immunological properties. In the present study, we demonstrate that intratumoral treatment with LTX-315 resulted in a complete regression and systemic immune response in a rat fibrosarcoma model. The treatment was T-cell dependent, and also resulted in an abscopal effect as demonstrated by the regression of distal non-treated lesions. Significant infiltration of CD8 + T cells was observed in both treated and non-treated lesions, as shown by immunohistochemical and flow cytometric analysis. LTX-315 rapidly killed the cells in vitro with a lytic mode of action followed by the subsequent release of Danger-Associated Molecular Pattern (DAMP) molecules such as HMGB1, ATP and Cytochrome c. Together, our data demonstrate that LTX-315 represents a new approach to cancer immunotherapy, which has the potential as a novel immunotherapeutic agent.